Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Martin, Schwickart"'
Autor:
Joel W. Neal, MD, PhD, Armando Santoro, MD, Maria Gonzalez-Cao, MD, PhD, Farah Louise Lim, MRCP, MD, Bruno Fang, MD, Ryan D. Gentzler, MD, MS, Jerome Goldschmidt, MD, Polina Khrizman, MD, Claudia Proto, MD, Shiven Patel, MD, MBA, FACP, Sonam Puri, MD, Stephen V. Liu, MD, Erminia Massarelli, MD, PhD, MS, Denise Williamson, MPH, Martin Schwickart, PhD, Christian Scheffold, MD, PhD, Svetlana Andrianova, MD, MPH, Enriqueta Felip, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 10, Pp 100666- (2024)
Introduction: We evaluated efficacy and safety of cabozantinib plus atezolizumab or cabozantinib alone in advanced NSCLC previously treated with an immune checkpoint inhibitor (ICI). Methods: COSMIC-021 (NCT03170960) is a phase 1b, multicenter study
Externí odkaz:
https://doaj.org/article/6812448f29344fa6a786793805d199c0
Autor:
Neeraj, Agarwal, Bradley, McGregor, Benjamin L, Maughan, Tanya B, Dorff, William, Kelly, Bruno, Fang, Rana R, McKay, Parminder, Singh, Lance, Pagliaro, Robert, Dreicer, Sandy, Srinivas, Yohann, Loriot, Ulka, Vaishampayan, Sanjay, Goel, Dominic, Curran, Ashok, Panneerselvam, Martin, Schwickart, Toni K, Choueiri, Sumanta, Pal
Publikováno v:
The Lancet Oncology. 23:899-909
Patients with metastatic castration-resistant prostate cancer have few treatment options after novel hormonal therapy (eg, abiraterone or enzalutamide). We aimed to evaluate cabozantinib, a tyrosine kinase inhibitor with immunomodulatory properties,
Autor:
Natalie J. Tigue, Lisa Bamber, John Andrews, Samantha Ireland, James Hair, Edward Carter, Sudharsan Sridharan, Jelena Jovanović, D. Gareth Rees, Jeremy S. Springall, Emilie Solier, Yi-Ming Li, Matthieu Chodorge, David Perez-Martinez, Daniel R. Higazi, Michael Oberst, Maureen Kennedy, Chelsea M. Black, Li Yan, Martin Schwickart, Shaun Maguire, Jennifer A. Cann, Lolke de Haan, Lesley L. Young, Tristan Vaughan, Robert W. Wilkinson, Ross Stewart
Publikováno v:
OncoImmunology, Vol 6, Iss 3 (2017)
Glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR) is part of a system of signals involved in controlling T-cell activation. Targeting and agonizing GITR in mice promotes antitumor immunity by enhancing the function of effec
Externí odkaz:
https://doaj.org/article/2ce1d1f11ec645bc9ff9055a90e162ac
Autor:
J. Randolph Hecht, Josep Tabernero, Aparna Raj Parikh, Yijia Wang, Zhong Wang, Martin Schwickart, Dominic Curran, Anwaar Saeed
Publikováno v:
Journal of Clinical Oncology. 41:TPS267-TPS267
TPS267 Background: The prognosis of patients with mCRC is poor, with a 5-year survival rate of 14% (American Cancer Society 2020). Patients who have progressed after front-line chemotherapy have limited treatment options. Regorafenib or trifluridine-
Autor:
Lin Tang, Wendy L. See, Lynn Quek, Chopra Vivek Saroj Kumar, Jorge F. DiMartino, Brian Avanzino, Martin Schwickart, Maria E. Figueroa, Kyle J. MacBeth, Bing Zheng
Publikováno v:
Experimental hematology. 98
Azacitidine and enasidenib are two therapies available for treatment of acute myelogenous leukemia (AML), and the mechanisms of action of these drugs involve alteration of aberrant DNA methylation. We hypothesized that a combination of these agents c
Autor:
Manuel Ugidos, Martin Schwickart, Jeevan K. Shetty, Anjan Thakurta, Maciej W Garbowski, John B. Porter, Sadanand Vodala, Rajasekhar N.V.S. Suragani, Alberto Risueño
Publikováno v:
Blood. 138:761-761
Introduction: Luspatercept inhibits select ligands of the TGF-β superfamily implicated in thalassemic erythropoiesis and promotes late-stage erythroid maturation (Suragani RN, et al. Nat Med 2014;20:408-414). This leads to greater red blood cell (RB
Autor:
Jennie Zhang, Adam J. Mead, Srdan Verstovsek, Giovanni Barosi, Ana Carolina Giuseppi, Marina Kremyanskaya, Martin Schwickart, Jeevan K. Shetty, Vincent Ribrag, Joseph Pariseau, Claire N. Harrison, Gabriel Miranda, Kelly McCaul, Jay Backstrom, Torsten G. Gerike, Jeanne Palmer, Jason Gotlib, Alessandro M. Vannucchi, Francesco Passamonti, Ruben A. Mesa, Jean-Jacques Kiladjian, Aaron T. Gerds
Publikováno v:
Blood. 136:47-48
Introduction: MF is a clonal stem cell disorder characterized by progressive bone marrow failure, extramedullary hematopoiesis, and debilitating constitutional symptoms. Approximately 60% of pts develop anemia within a year of diagnosis; pts who are
Autor:
Alexander V. Ratushny, Harish N. Ramanathan, Melih Acar, Martin Schwickart, Diana Ronai Dunshee, Daniel Menezes, Rajasekhar N.V.S. Suragani, Kyle J. MacBeth, Remco Loos, Roberto A Abbiati, C.C. Santini, Madhulika Jupelli
Publikováno v:
Blood. 136:18-19
Luspatercept is a recombinant fusion protein that binds and sequesters several endogenous transforming growth factor-beta superfamily ligands, including growth differentiation factor 11, thereby diminishing Smad2/3 signaling in target cells involved
Autor:
Martin Schwickart, Xuemei Zhao, Mark Cameron, Mark Ware, Karin Regnstrom, Edward O’Connor, Judy Shih, Stephanie Fraser
Publikováno v:
The AAPS Journal. 19:682-691
Numerous advances in ligand binding assay (LBA) real-time measurement technologies have been made within the last several years, ranging from the development of novel platforms to drive technology expansion to the adaptation of existing platforms to
Autor:
Martin Schwickart, Inna Vainshtein
Publikováno v:
Nijkamp and Parnham's Principles of Immunopharmacology ISBN: 9783030108090
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ba4bd095a50e7ed7d5bbce1f84d2d405
https://doi.org/10.1007/978-3-030-10811-3_15
https://doi.org/10.1007/978-3-030-10811-3_15